◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › I › INBX

Inhibrx Biosciences, Inc. (INBX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-13

Inhibrx Biosciences, Inc. (INBX) operates in the BIOTECHNOLOGY industry and is headquartered in La Jolla, United States with about 109 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, INBX reported $1M in revenue and ($140M) in net income.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.

Interactive charts & full statements → Open the INBX valuation workbench →

INBX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total Revenue	$0M	$1M	$0M	$2M	$2M	$7M	$13M	$9M	$9M	$8M	$7M
Gross Profit	—	($1M)	($2M)	$1M	($108M)	$7M	($61M)	($39M)	($25M)	($17M)	($10M)
Gross Margin %	—	-91.0%	-1042.5%	33.8%	-4926.7%	100.0%	-473.8%	-426.9%	-289.2%	-204.0%	-154.9%
Operating Income (EBIT)	($128M)	($135M)	($331M)	($219M)	($129M)	($77M)	($67M)	($41M)	($30M)	($20M)	($12M)
Operating Margin %	—	-10386.5%	-165724.0%	-12178.9%	-5890.4%	-1058.8%	-526.6%	-450.4%	-343.4%	-235.1%	-182.2%
Net Income	($138M)	($140M)	$1.7B	($241M)	($145M)	($82M)	($76M)	($51M)	($31M)	($19M)	($8M)
Net Margin %	—	-10773.5%	843786.0%	-13408.9%	-6625.3%	-1130.8%	-590.5%	-565.3%	-362.6%	-231.7%	-124.0%
EBITDA	($120M)	($125M)	$1.7B	($207M)	($126M)	($77M)	($64M)	($40M)	($29M)	($19M)	($12M)
Earnings Per Share (EPS)	$-8.88	$-9.04	$116.58	$-5.12	$-3.62	$-2.15	$-2.99	$-1.41	$-1.15	$-0.68	$-0.23
Shares Outstanding (M)	16M	15M	14M	47M	40M	38M	25M	37M	27M	29M	37M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INBX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$1M	$0M	$0M	$0M
Gross Profit	—	($1M)	($1M)	($1M)	$1M	($1M)	($1M)	($1M)
Gross Margin %	—	—	—	—	49.1%	—	-589.0%	—
Operating Income (EBIT)	($32M)	($31M)	($31M)	($34M)	($27M)	($43M)	($50M)	($47M)
Operating Margin %	—	—	—	—	-2106.8%	—	-49928.0%	—
Net Income	($37M)	($33M)	($33M)	($35M)	($29M)	($43M)	($48M)	($44M)
Net Margin %	—	—	—	—	-2204.2%	—	-47865.0%	—
EBITDA	($30M)	($29M)	($29M)	($31M)	($25M)	($40M)	($47M)	($43M)
Earnings Per Share (EPS)	$-2.34	$-2.15	$-2.12	$-2.28	$-1.85	$-2.80	$-3.31	$-2.84
Shares Outstanding (M)	16M	16M	15M	15M	15M	15M	14M	15M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INBX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash from Operations (CFO)	($132M)	($130M)	($194M)	($193M)	($115M)	($80M)	($48M)	($32M)	($23M)	($19M)	($18M)
Capital Expenditures (CapEx)	$0M	$0M	$3M	$5M	$1M	$1M	$1M	$2M	$1M	$1M	$0M
Free Cash Flow (FCF)	($132M)	($130M)	($197M)	($198M)	($116M)	($81M)	($49M)	($34M)	($25M)	($20M)	($18M)
FCF Margin %	—	-9986.5%	-98503.0%	-10994.6%	-5291.4%	-1122.8%	-385.2%	-372.7%	-285.3%	-239.4%	-274.8%
Dividends Paid	—	—	—	—	—	—	—	—	$1M	$1M	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INBX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($30M)	($38M)	($30M)	($34M)	($30M)	($36M)	($44M)	($30M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($30M)	($38M)	($30M)	($34M)	($30M)	($36M)	($44M)	($31M)
FCF Margin %	—	—	—	—	-2304.1%	—	-43736.0%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INBX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total Assets	$154M	$146M	$181M	$308M	$291M	$150M	$144M	$26M	$10M	$17M	$21M
Cash & Cash Equivalents	$133M	$124M	$153M	$278M	$274M	$131M	$129M	$12M	$2M	$13M	$20M
Total Liabilities	$207M	$138M	$47M	$264M	$233M	$98M	$68M	$120M	$68M	$40M	$20M
Total Debt (Short + Long-Term)	$179M	$103M	$2M	$209M	$2M	$2M	$2M	$5M	$6M	$5M	$4M
Total Shareholders' Equity	($53M)	$8M	$134M	$44M	$58M	$52M	$75M	($94M)	($58M)	($29M)	($9M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INBX viewer.

Other Companies in BIOTECHNOLOGY

KLRA · Kailera Therapeutics, Inc. Common Stock — $2 billion
ABSI · Absci Corp — $2 billion
TSHA · Taysha Gene Therapies Inc — $2 billion
ANAB · AnaptysBio Inc — $2 billion
SNDX · Syndax Pharmaceuticals Inc — $2 billion
KARD · Kardigan, Inc. Common Stock — $2 billion
INVA · Innoviva Inc — $2 billion
BCAX · Bicara Therapeutics Inc. Common Stock — $1 billion

← INBS All “I” companies INCE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.